Table 2. Complications, Treatment, and Clinical Outcomes of Patients with SARS-CoV-2 Infection.
| All patients (n=98) | ICU (n=13) | Non-ICU (n=85) | p value | |
|---|---|---|---|---|
| Complications | ||||
| ARDS | 18 (18.4) | 13 (100) | 5 (5.9) | <0.001 |
| Septic shock | 9 (9.2) | 9 (69.2) | 0 (0) | <0.001 |
| Acute cardiac injury | 11 (11.2) | 9 (69.2) | 2 (2.4) | <0.001 |
| Acute kidney injury | 9 (9.2) | 8 (61.5) | 1 (1.2) | <0.001 |
| Treatment | ||||
| Oxygen | 37 (37.8) | 12 (92.3) | 25 (29.4) | <0.001 |
| HFNC | 12 (12.2) | 7 (53.8) | 5 (5.9) | <0.001 |
| IMV | 11 (11.2) | 11 (84.6) | 0 (0) | <0.001 |
| CRRT | 3 (3.1) | 3 (23.1) | 0 (0) | 0.002 |
| ECMO | 4 (4.1) | 4 (30.8) | 0 (0) | <0.001 |
| Antibiotics | 98 (100) | 13 (100) | 85 (100) | |
| Lopinavir/ritonavir | 97 (99.0) | 13 (100) | 84 (98.8) | 1.000 |
| Hydroxychloroquine | 79 (80.6) | 13 (100) | 66 (77.6) | 0.067 |
| Glucocorticoid | 18 (18.4) | 10 (76.9) | 8 (9.4) | <0.001 |
| Clinical outcomes | 0.004 | |||
| Remains in hospital | 57 (58.2) | 7 (53.8) | 50 (58.8) | |
| Discharged | 30 (30.6) | 1 (7.7) | 29 (34.1) | |
| Died | 5 (5.1) | 4 (30.8) | 1 (1.2) | |
| Transferred | 6 (6.1) | 1 (7.7) | 5 (5.9) |
ARDS, acute respiratory distress syndrome; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; HFNC, high-flow nasal cannula; ICU, intensive care unit; IMV, invasive mechanical ventilation; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Data are presented as a number (percentage).